Liver Metastasis Colon Cancer Clinical Trial
Official title:
Surgery Outcome Treated by Neo-adjuvant Chemotherapy FOLFOXIRI Regimen in Colorectal Cancer With Liver-limited Synchronous Metastases
This single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mCRC) using FOLFOXIRI neoadjuvant regimen and to assess the other outcome including the response rate, the survival rate and the safety profile.
Patients with liver-only metastases colorectal cancer could potentially be cured following surgical resection of metastases. Recent evidence suggest that a triplet chemotherapy regimen, FOLFOXIRI has been associated with higher R0 resection. Eighty-nine eligible patients will be recruited at Cho Ray hospital in Vietnam. Patients will receive neoadjuvant FOLFOXIRI regimen every two weeks for up to 12 cycles and will undergo periodic imaging studies. The resectability of liver metastases will be assessed by a multidisciplinary team comprised of digestive surgeons, hepato-biliary surgeons, radiologists, and oncologists. This study will be helpful to establish a standard chemotherapy regimen for patients with liver-limited metastatic colorectal cancer. Moreover, this study will assess the surgical outcome, the response rate, the survival rate, the safety of triple drug chemotherapy and the association between conversion operable disease and various survival rate and patient's characteristics. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03562234 -
The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases
|
||
Recruiting |
NCT03732235 -
TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer
|
||
Recruiting |
NCT06126419 -
Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration
|
N/A | |
Active, not recruiting |
NCT05616039 -
I-FIGS Feasibility Study
|
N/A | |
Withdrawn |
NCT05175092 -
Living Donor Liver Transplantation for CRC Liver Metastases
|
N/A | |
Recruiting |
NCT04798898 -
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
|
N/A | |
Not yet recruiting |
NCT06071052 -
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
|
N/A | |
Not yet recruiting |
NCT06053996 -
Hepatopulmonary Radio-sterilization With Immunotherapy
|
N/A | |
Recruiting |
NCT04491929 -
Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases
|
||
Not yet recruiting |
NCT06050200 -
TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery
|
N/A | |
Enrolling by invitation |
NCT03444194 -
Treatment Response Evaluation in Patients With Non-resectable Colorectal Liver Metastases A Feasibility Study
|
N/A | |
Not yet recruiting |
NCT05884723 -
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
|
N/A | |
Not yet recruiting |
NCT06185556 -
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
|
Phase 2/Phase 3 | |
Recruiting |
NCT05755672 -
On-treatment Biomarkers in Metastatic Colorectal Cancer for Life
|
||
Recruiting |
NCT04595266 -
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
|
Phase 2 | |
Recruiting |
NCT04701281 -
Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05775146 -
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
|
Phase 2 | |
Recruiting |
NCT06200831 -
Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases
|
N/A | |
Active, not recruiting |
NCT04046445 -
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
|
Phase 1 |